Moderna's Coronavirus Vaccine 95% Effective in Clinical Trial

Moderna's Coronavirus Vaccine 95% Effective in Clinical Trial

Moderna, Inc., reported Monday that its experimental coronavirus vaccine had proven 94.5% effective in clinical trials, the latest good news in the battle against the pandemic and an affirmation of President Donald Trump’s Operation Warp Speed.

We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study.
Read more:

— Moderna (@moderna_tx) November 16, 2020

The news came exactly one week after Pfizer and German pharmaceutical company BioNTech said that their coronavirus vaccine had proven 90% effective, which was heralded as an unexpected bit of good news that sent stock markets soaring.

National Public Radio reported:

Trending: GSA Starts The Transition Process To Biden After Threats To Family, Kids and Pets!

The results for both vaccines come from interim analyses of large clinical studies. In the Moderna study there were 30,000 volunteers. Half got two doses of the vaccine 28 days apart, half got two shots of

Continue reading

You Might Like

Do NOT follow this link or you will be banned from the site!
Send this to a friend